AlphAIalphai — Financial news for AI agents
GlobeNewswireNOV 172 min read$CLDI

Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025

SAN DIEGO, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Calidi Biotherapeutics, Inc. ( "Calidi" or the "Company" ) ( NYSE American: CLDI ) , a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, ...

Original reporting
GlobeNewswire · Inc, Calidi Biotherapeutics
Published Nov 17, 2025, 1:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 17, 2025, 1:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Calidi Biotherapeutics Announces Exclusive Live Investor Webinar and Q&A Session on November 19, 2025 — source image
Source · www.globenewswire.com
Decision brief

The 30-second read

$CLDINeutralMed
01

Why it matters

The upcoming webinar signifies active investor engagement, which could temporarily influence stock trading volume and price.

02

Market read

The event is relevant primarily to current and prospective investors in Calidi Biotherapeutics and the biotech sector.

03

What to watch

Market conditions and broader biotech sector trends could overshadow company-specific events.

Timing: High, as the webinar is scheduled for November 19, 2025.

Background

Calidi Biotherapeutics is a clinical-stage biotech company focusing on targeted genetic therapies.

Company-level read

Ticker impact

$CLDINeutralMedium confidence
Context

The news pertains directly to Calidi Biotherapeutics, Inc. (NYSE American: CLDI), and may influence its stock performance.

Expected impact

Potential short-term increase in stock volatility; possible moderate price uptick if the webinar is well-received.

Evidence & confidence

While the event indicates active investor engagement, the direct impact on stock price depends on the content and market reception. No immediate fundamental changes are announced.

Market effects

Sector

Potential positive sentiment in biotech and healthcare sectors due to increased investor engagement.

Regional

Limited regional impact; primarily relevant to US-based investors.

Global

Low; the event is company-specific and does not have global market implications.

Counterpoint

What could challenge this read

The webinar may not lead to significant market movement if the content does not meet investor expectations.

Key entities

  • Company
    Calidi Biotherapeutics, Inc.

    A biotech company developing targeted therapies with genetic medicine.

Read at source← All news

Related articles

AUG 13
$CLDIMed

Calidi Biotherapeutics, Inc. (CLDI): Results of Operations and Financial Condition

Calidi Biotherapeutics, Inc. (CLDI) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Received positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a firs

SEC EDGAR 8-K4 min
JUL 21
$CLDIMed

Calidi Biotherapeutics, Inc: Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers

Calidi Biotherapeutics (NYSE American: CLDI) reported a positive US FDA pre-IND outcome for CLD-401, agreeing on pharmacology, toxicology, CMC and phase I protocol strategy. The company targets first patient dosing in Q1 2027 and expects first data in Q2 2027. It also cited new RedTail in situ TCE data, added a board member, and cut G&A by about $1M from Q1 2025 to Q1 2026.

finanznachrichten.de4 min
AUG 13
Med

Prysmian Cable Manufacturing Expands North Carolina Facility

Prysmian is investing over $1 billion to expand its Catawba County, North Carolina facility in Claremont, adding 385 jobs, according to Governor Josh Stein. The expansion is expected to take 20-24 months and more than double U.S. fiber optic capacity, including glass preform and fiber, and increase cable production. Prysmian employs about 680 there.

marinetechnologynews.com2 min
AUG 13
$NFLXMed

Netflix Shutters Oxenfree Studio Night School just Six Weeks after its Final Horror Game, Unhinged, Hit the Service

Netflix will shut down Night School Studio, developer of Oxenfree and Afterparty, six weeks after releasing Unhinged, and plans to close Moonloot, a Helsinki studio it founded in 2022. Netflix says it is restructuring its internal games team to focus on kids, party, story-driven and mainstream titles, without disclosing job counts. It acquired Night School in 2021.

wccftech.com6 min
AUG 13
$NFLXMed

Netflix Kills Oxenfree Studio Right After New Release

Netflix said it is shutting down Night School Studio, acquired in 2021 under Netflix Games, about a month after the release of mobile game Unhinged. Netflix also plans to close Moonloot and cut some internal gaming staff, citing organizational changes to focus on party, kids, mainstream-licensed and story games, according to a Netflix spokesperson.

dualshockers.com4 min